scholarly article | Q13442814 |
P50 | author | Andrew Kenneth Burroughs | Q18385218 |
Emmanuel Tsochatzis | Q28320718 | ||
James Carpenter | Q52569383 | ||
P2093 | author name string | Jiannis Vlachogiannakos | |
Cristina Rigamonti | |||
Maurille Feudjo | |||
P2860 | cites work | Ursodeoxycholic acid for primary biliary cirrhosis | Q24241945 |
Multilevel modelling of medical data | Q28206769 | ||
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
Ursodeoxycholic acid for primary biliary cirrhosis. | Q32064450 | ||
Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
Ursodeoxycholic acid: Mechanism of action and novel clinical applications | Q37012207 | ||
Survival following the development of ascites and/or peripheral oedema in primary biliary cirrhosis: a staged prognostic model | Q38937793 | ||
Prediction of short-term survival with an application in primary biliary cirrhosis | Q39085766 | ||
Surrogate endpoints in clinical trials: definition and operational criteria | Q41310696 | ||
Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study | Q42551010 | ||
Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines | Q43253298 | ||
Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial | Q44110703 | ||
Ursodeoxycholic acid and histological progression in primary biliary cirrhosis | Q44671802 | ||
Predicting the advent of ascites and other complications in primary biliary cirrhosis: a staged model approach. | Q44706114 | ||
Prognosis in primary biliary cirrhosis: model for decision making | Q46316848 | ||
The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 | ||
A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis | Q51586165 | ||
Criteria for the validation of surrogate endpoints in randomized experiments. | Q52230235 | ||
Statistical validation of intermediate endpoints for chronic diseases | Q68115549 | ||
Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis | Q71995039 | ||
A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid | Q72189521 | ||
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups | Q72638625 | ||
Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC | Q72789964 | ||
Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver | Q73715566 | ||
Primary biliary cirrhosis | Q81246142 | ||
P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | primary biliary cholangitis | Q1072420 |
P304 | page(s) | 139763 | |
P577 | publication date | 2013-07-24 | |
P1433 | published in | BioMed Research International | Q17509958 |
P1476 | title | Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy | |
P478 | volume | 2013 |
Q36193470 | Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis |
Q38616218 | Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation |
Q57301971 | Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure |
Q51300509 | Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats. |
Search more.